Bulletin
Investor Alert

Frequency Therapeutics Inc.

NAS: FREQ

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Apr 12, 2021, 7:49 p.m.

/zigman2/quotes/214411420/composite

$

9.51

Change

+0.02 +0.21%

Volume

Volume 6,655

Quotes are delayed by 20 min

/zigman2/quotes/214411420/composite

Previous close

$ 10.84

$ 9.49

Change

-1.35 -12.45%

Day low

Day high

$9.30

$10.84

Open

52 week low

52 week high

$7.34

$58.37

Open

Company Description

Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David ...

Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Valuation

Price to Sales Ratio

30.75

Price to Book Ratio

6.22

Enterprise Value to Sales

26.04

Total Debt to Enterprise Value

0.05

Efficiency

Revenue/Employee

425,103.00

Income Per Employee

-304,724.00

Receivables Turnover

64.60

Total Asset Turnover

0.15

Liquidity

Current Ratio

8.45

Quick Ratio

8.45

Cash Ratio

8.27

Profitability

Gross Margin

95.73

Operating Margin

-74.49

Pretax Margin

-71.59

Net Margin

-71.68

Return on Assets

-10.87

Return on Equity

-14.73

Return on Total Capital

-13.58

Return on Invested Capital

-13.08

Capital Structure

Total Debt to Total Equity

23.89

Total Debt to Total Capital

19.29

Total Debt to Total Assets

17.37

Long-Term Debt to Equity

23.69

Long-Term Debt to Total Capital

19.12

Officers and Executives

Name Age Officer Since Title
Mr. David L. Lucchino 50 2014 President, CEO, Secretary & Director
Mr. Richard Mitrano 48 2016 Vice President-Finance & Operations
Mr. Peter P. Pfreundschuh 50 2020 Chief Financial Officer
Dr. Dana Charles Hilt 66 2019 Chief Medical Officer
Dr. Jeffrey Hrkach 54 - Senior Vice President-Technology Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/01/2021 David L. Lucchino
President and CEO; Director
192   Disposition at $52.11 per share. 10,005
03/01/2021 David L. Lucchino
President and CEO; Director
4,202   Disposition at $51.76 per share. 217,495
03/01/2021 David L. Lucchino
President and CEO; Director
2,688   Disposition at $50 per share. 134,400
03/01/2021 David L. Lucchino
President and CEO; Director
1,255   Disposition at $48.85 per share. 61,306
03/01/2021 David L. Lucchino
President and CEO; Director
1,079   Disposition at $47.84 per share. 51,619
03/01/2021 David L. Lucchino
President and CEO; Director
9,416   Derivative/Non-derivative trans. at $0.61 per share. 5,743
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $57.5 per share. 317,285
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $55 per share. 303,490
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $52.5 per share. 289,695
02/08/2021 David L. Lucchino
President and CEO; Director
16,554   Derivative/Non-derivative trans. at $0.61 per share. 10,097
02/03/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $50 per share. 275,900
02/03/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $47.5 per share. 262,105
02/03/2021 Christopher R. Loose
Chief Scientific Officer
2,000   Disposition at $47.19 per share. 94,380
02/03/2021 David L. Lucchino
President and CEO; Director
11,036   Derivative/Non-derivative trans. at $0.61 per share. 6,731
02/02/2021 David L. Lucchino
President and CEO; Director
9   Disposition at $47.36 per share. 426
02/02/2021 David L. Lucchino
President and CEO; Director
1,709   Disposition at $46.84 per share. 80,049
02/02/2021 David L. Lucchino
President and CEO; Director
3,800   Disposition at $45.76 per share. 173,888
02/02/2021 Christopher R. Loose
Chief Scientific Officer
8,000   Disposition at $45.02 per share. 360,160
02/02/2021 David L. Lucchino
President and CEO; Director
5,518   Derivative/Non-derivative trans. at $0.61 per share. 3,365
02/01/2021 David L. Lucchino
President and CEO; Director
2,702   Disposition at $44.58 per share. 120,455
02/01/2021 David L. Lucchino
President and CEO; Director
8,900   Disposition at $43.71 per share. 389,019
02/01/2021 David L. Lucchino
President and CEO; Director
18,600   Disposition at $42.85 per share. 797,010
02/01/2021 David L. Lucchino
President and CEO; Director
2,900   Disposition at $41.29 per share. 119,741
02/01/2021 David L. Lucchino
President and CEO; Director
33,102   Derivative/Non-derivative trans. at $0.61 per share. 20,192
01/27/2021 David L. Lucchino
President and CEO; Director
9,196   Disposition at $42.5 per share. 390,830
01/27/2021 Christopher R. Loose
Chief Scientific Officer
8,000   Disposition at $42.5 per share. 340,000
01/27/2021 David L. Lucchino
President and CEO; Director
9,196   Derivative/Non-derivative trans. at $0.61 per share. 5,609
01/06/2021 David L. Lucchino
President and CEO; Director
9,496   Disposition at $40 per share. 379,840
01/06/2021 David L. Lucchino
President and CEO; Director
2,319   Disposition at $39.37 per share. 91,299
01/06/2021 David L. Lucchino
President and CEO; Director
4,164   Disposition at $38.26 per share. 159,314
01/06/2021 David L. Lucchino
President and CEO; Director
10,707   Disposition at $37.45 per share. 400,977
01/06/2021 David L. Lucchino
President and CEO; Director
900   Disposition at $36.13 per share. 32,517
01/06/2021 David L. Lucchino
President and CEO; Director
27,586   Derivative/Non-derivative trans. at $0.61 per share. 16,827
01/04/2021 David L. Lucchino
President and CEO; Director
100   Disposition at $35.46 per share. 3,546
01/04/2021 David L. Lucchino
President and CEO; Director
11,763   Disposition at $33.81 per share. 397,707
01/04/2021 David L. Lucchino
President and CEO; Director
22,241   Disposition at $32.89 per share. 731,506
01/04/2021 David L. Lucchino
President and CEO; Director
14,477   Derivative/Non-derivative trans. at $0.61 per share. 8,830
01/04/2021 David L. Lucchino
President and CEO; Director
3,913   Derivative/Non-derivative trans. at $0.61 per share. 2,386
12/24/2020 Timothy Joseph Barberich
Director
102,089   Gift at $0 per share. 0
12/17/2020 David L. Lucchino
President and CEO; Director
1,120   Disposition at $42.64 per share. 47,756
12/17/2020 Christopher R. Loose
Chief Scientific Officer
2,000   Disposition at $42.5 per share. 85,000
12/17/2020 Christopher R. Loose
Chief Scientific Officer
6,000   Disposition at $40 per share. 240,000
12/17/2020 David L. Lucchino
President and CEO; Director
1,120   Derivative/Non-derivative trans. at $0.61 per share. 683
/news/latest/company/us/freq

MarketWatch News on FREQ

  1. Requency Therapeutics stock price target cut to $35 from $79 at B. Riley

    8:16 a.m. March 24, 2021

    - Tomi Kilgore

  2. Frequency Therapeutics upgraded to overweight from neutral at J.P. Morgan

    9:07 a.m. Jan. 27, 2021

    - Tomi Kilgore

  3. Frequency Therapeutics stock price target raised to $56 from $27 at J.P. Morgan

    9:07 a.m. Jan. 27, 2021

    - Tomi Kilgore

  4. Frequency Therapeutics started at outperform with $36 stock price target at Oppenheimer

    7:16 a.m. July 14, 2020

    - Tomi Kilgore

  5. Frequency Therapeutics downgraded to neutral from overweight at J.P. Morgan

    6:45 a.m. May 18, 2020

    - Tomi Kilgore

  6. Frequency Therapeutics started at overweight with $25 stock price target at J.P. Morgan

    8:09 a.m. Oct. 28, 2019

    - Tomi Kilgore

/news/nonmarketwatch/company/us/freq

Other News on FREQ

  1. GEO, OCGN, SOS and CXW among midday movers

    12:44 p.m. April 7, 2021

    - Seeking Alpha

  2. Wall Street Breakfast: What Moved Markets

    7:29 a.m. March 27, 2021

    - Seeking Alpha

  3. RIOT, SRNE, GNUS and IPHI among premarket gainers

    8:23 a.m. March 24, 2021

    - Seeking Alpha

  4. IONS, GNUS, UPST and FNKO among midday movers

    12:41 p.m. March 23, 2021

    - Seeking Alpha

  5. Why Frequency Therapeutics Stock Is Crashing Today

    12:12 p.m. March 23, 2021

    - Motley Fool

  6. QuantumScape, MP Materials among premarket losers' pack

    8:30 a.m. March 23, 2021

    - Seeking Alpha

  7. Frequency Therapeutics upgraded to Overweight at JPMorgan

    9:29 a.m. Jan. 27, 2021

    - Seeking Alpha

  8. Seeking Alpha Catalyst Watch

    4:00 p.m. Jan. 15, 2021

    - Seeking Alpha

  9. 10-Q: FREQUENCY THERAPEUTICS, INC.

    8:44 a.m. Nov. 16, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  10. Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

    1:04 p.m. Oct. 16, 2020

    - Seeking Alpha

  11. Loading more headlines...

At a Glance

Frequency Therapeutics, Inc.

19 Presidential Way

2nd floor

Woburn, Massachusetts 01801

Phone

1 8663891970

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$36.98M

Net Income

$-26.51M

2020 Sales Growth

27.8%

Employees

87.00

/news/pressrelease/company/us/freq

Press Releases on FREQ

  1. Loading more headlines...
Link to MarketWatch's Slice.